NantKwest Inc: Jumps on FDA nod to expand COVID-19 vaccine study

NK

12/02/2021 13:24

** Immunotherapy co's  NK.O  shares jump 13.2% to $29.49
premarket
    ** NK and partner ImmunityBio on Thursday aftermarket
announced that the U.S. FDA had authorized the expansion of an
early-stage study testing their T-cell COVID-19 vaccine
 urn:newsml:reuters.com:*:nBwnf5LRa
    ** Says FDA authorized the expansion of a trial of the
subcutaneous injection version of the vaccine and also allowed a
second early-stage study that will examine the addition of an
oral boost to the subcutaneous prime administration
    ** As a result, cos to enroll another 105 participants in
the U.S. trials of the vaccine candidate
    ** NK announced merger with privately held ImmunityBio in
December last year  urn:newsml:reuters.com:*:nL4N2J12O7
    ** NK shares had surged 95.4% YTD, as of the last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))